Navigation Links
Pennsaid(R) Phase 3 study results to be published in leading international PAIN journal
Date:4/23/2009

MISSISSAUGA, ON, April 23 /PRNewswire-FirstCall/ - Nuvo Research Inc. (TSX: NRI), a Canadian drug development company focused on the research and development of drug products delivered to and through the skin using its topical and transdermal drug delivery technologies, today announced that study results demonstrating that the Company's lead product, Pennsaid, a topical non-steroidal anti-inflammatory drug (NSAID), is an efficacious treatment for the symptoms of osteoarthritis of the knee will be published in the June 2009 edition of PAIN.

PAIN is the world's leading publication on pain research and treatments and the official journal of the International Association for the Study of Pain (IASP(R)). The IASP, founded in 1973, is the leading professional forum for science, practice, and education in the field of pain and has more than 6,500 members in 118 countries who are professionals involved in the research, diagnosis and treatment of pain.

The scientific article details Nuvo's previously announced study results, which demonstrated that Pennsaid is efficacious for the relief of symptoms in patients with knee osteoarthritis. In addition, the study demonstrated that Pennsaid is as effective as oral diclofenac at relieving knee osteoarthritis symptoms but with less NSAID-related systemic toxicity. The article, titled, "Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis", was written by Dr. Lee Simon as lead author, and Dr. Lisa Grierson, Zahid Naseer, Dr. Arthur A.M. Bookman, M.D., and Dr. J. Zev Shainhouse as co-authors. It is currently available on the PAIN website.

"The publication of this article in the premier international pain journal further confirms Pennsaid's unique and compelling efficacy and safety profile among all other topical NSAIDs," said Dr. Brad Galer, Vice President and General Manager of Nuvo
'/>"/>

SOURCE Nuvo Research Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Nuvo Research Announces Successful Completion Of All Pennsaid(R) Studies
2. FDA Accepts Nuvos Resubmission For Pennsaid(R)
3. Ovation further advances development pipeline with new phase III epilepsy study
4. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
5. Mannatech Launches Phase One of New Sales and Training Tools
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Manic phase of bipolar disorder benefits from breast cancer medication
8. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
9. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
10. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
11. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014 This Method to ... health effects for practitioners. , The Hypopresive ... of Science and Movement specializing in physical rehabilitation. ... pelvic floor reeducation that traditional abdominal exercises after ... Recti, Prolepses, etc. , The Hipopressives exercises pull ...
(Date:10/31/2014)... October 31, 2014 Energy Textiles has ... The new gear is now available online, and Energy ... benefits of Celliant infrared-active athletic gear over compression gear. ... another contract has been signed for Under Armour to ... the next eight years. In light of this decision, ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 2014 Gold Medal Wine Club ... but tasteful gifts for the wine novice and enthusiasts on ... Gift Giving Special , which Early Bird shoppers receive discounts ... Club Gift membership. , Gift Givers must place their ... Besides offering discounts, Gold Medal Wine Club adds more value ...
(Date:10/31/2014)... a drug combination that can trigger the self-destruct process ... new treatments, according to research that will be presented ... in Liverpool next week*. , When healthy cells are ... culminating in self destruction. But cancer cells swerve away ... that cells grow out of control – causing tumours ...
Breaking Medicine News(10 mins):Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3Health News:Compression Gear--Is There a Better Alternative? 2Health News:Compression Gear--Is There a Better Alternative? 3Health News:Compression Gear--Is There a Better Alternative? 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Gold Medal Wine Club now offering Early Bird Gift Giving Special for Holidays 2Health News:Scientists trigger self-destruct switch in lung cancer cells 2
... ( www.PatientAssistance.com ) has released initial survey results on diabetes ... ... Baton Rouge, LA – November 20, 2008 – ... awareness amongst the predominantly uninsured and underinsured visitors of ...
... Amy Rees Anderson, was invited to participate with U.S. Secretary of ... Care. , ... Salt Lake City (Vocus) November 20, ... with U.S. Secretary of Health, Michael Leavitt, in the 2008 National ...
... for the prestigious "Super Dentist" award given to elite dentists in ... top practitioner in the area of Cosmetic Dentistry. , ... ... Austin Smiles was recently nominated as a "Texas Monthly ...
... the frequency of exacerbations in patients with moderate to ... as 35 percent, according to a London-based study. ... macrolide therapy, reducing exacerbation frequency and severity with moderate ... Terence A. R. Seemungal, Ph.D., and Jadwiga Wedzicha, M.D., ...
... NEW YORK Nov. 19, 2008 The American ... and largest non-governmental funder of cancer research and discovery ... Honor, to four Americans who have made outstanding contributions ... will receive their awards at a ceremony during the ...
... says about 40% returned positive results in review of ... Colorectal cancer screening detects 40 percent of cancers and ... Finnish Cancer Registry researchers. , They studied 106,000 people, ... colorectal cancer screening program was in identifying unrecognized disease. ...
Cached Medicine News:Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 2Health News:Initial Survey Findings on Diabetes Awareness Released by PatientAssistance.com 3Health News:MediConnect Participates in 2008 National Health Summit 2Health News:Texas Super Dentist Awards Announced--Dr. Michael McCarty From Austin Smiles Is Awarded For The Third Year In A Row 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 2Health News:Long-term antibiotics reduce COPD exacerbations, raise questions 3Health News:Scientists honored for contributions to cancer fight 2Health News:Scientists honored for contributions to cancer fight 3Health News:Scientists honored for contributions to cancer fight 4Health News:Scientists honored for contributions to cancer fight 5Health News:Colorectal Cancer Screens Detect Unrecognized Disease 2
(Date:10/31/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ... on the development of oral drug delivery systems, ... call to discuss the clinical results from its ... proprietary oral insulin capsules, to treat type 1 ... a.m. Eastern time. Shareholders and other ...
(Date:10/31/2014)... MOUNTAIN VIEW, Calif. , Oct. 31, 2014 /PRNewswire/ ... amyotrophic lateral sclerosis (ALS) patients initiate text and email ... based upon a patent-pending technology invented by ThynkWare,s founder, ... virtual assistant on a smartphone device. This technology allows ... ways using only the power of thought. ...
(Date:10/31/2014)... 2014 Migranade, Inc. announced today the new ... the 36 million U.S. migraine sufferers November, 2014. The ... the actual cause of migraines and not just the ... the source Migranade is assured to be a game ... is available at http://www.migranade.com and will soon ...
Breaking Medicine Technology:Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3ThynkWare Speech Helps Those with ALS and Locked-In Syndrome Translate Thought to Speech on Their Smartphone Devices 2Game Changing Migraine Medication To Be Available November 2014 2
... 16, 2011  Senior citizens and people living with physical ... power wheelchairs if the Administration enacts a restrictive prepayment ... Medicare system, according to consumer advocates and home medical ... Centers for Medicare and Medicaid Services (CMS) has listed ...
... 16, 2011  Veran Medical Technologies announced today the ... bi-planar virtual fluoroscopy view used to navigate multiple ... its kind in pulmonology, enabling physicians to view ... in a fluoro-like view without any radiation being ...
Cached Medicine Technology:Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 2Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 3Congress Asked to Stop Policy That Would Restrict Access to Mobility Assistance for Medicare Beneficiaries in New York 4Veran Medical Technologies Launches New SPiN Drive™ Application for Bi-Planar Virtual Fluoroscopy View 2
... delivers a solid-state green laser ... and plugs into any standard ... and extreme portability, the unit ... Nidek Phaco Emulsification System CV-24000 ...
There are many reasons to choose the CardioGenesis 2000 Holmium:YAG Laser System for TMR in your hospital or medical facility. Among the first is the CardioGenesis commitment to deliver the highest q...
Total T3 EIA Thyroid Function 025-BC-1005...
... The anti-TG test kit is a ... microplate format. It is designed for the ... thyroglobulin (TG) in serum or plasma. The ... 1: Calibrators, controls and patient samples are ...
Medicine Products: